Clinical efficacy of apatinib in treating refractory triple-negative advanced breast cancer

Xiaorui Wang, Xu Wang, Yehui Shi, Chen Wang, Zhongsheng Tong

    Research output: Contribution to journalArticle


    Objective: To evaluate the effectiveness and safety of using apatinib in the treatment of refractory triple-negative advanced breast cancer. Methods: Eight cases of advanced triple-negative breast cancer patients confirmed via histopathology, who were previously treated with anthracycline, taxane, gemcitabine, capecitabine, and 500 mg/d apatinib in our hospital from July 2015 to November 2016, were retrospectively analyzed. The time of disease progress, effective rate, clinical benefits, and side effects were observed. Results: Eight patients were administrated with an average of 4 treatment cycles, and the effects were evaluated after 2 weeks. Four patients exhibited partial remission, 3 had a stable disease, and 1 had a progressive disease. The disease control rate was 87.5%, and the median progression free survival was 4.2 months. The main side effects were hand-foot syndrome (3/8), bone marrow arrest (4/8), hypertension (2/8), proteinuria (3/8), hemoptysis (1/8), nausea (2/8), and fatigue (2/8). Most of these side effects were tolerable. Conclusion: Apatinib can effectively and tolerably prolong survival time and improve the quality of life of patients with advanced triple-negative breast cancer.

    Original languageEnglish (US)
    Pages (from-to)769-772
    Number of pages4
    JournalChinese Journal of Clinical Oncology
    Issue number15
    StatePublished - Jan 1 2017



    • Apatinib
    • Breast cancer
    • Metastasis
    • Molecular targeted therapy

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this